Systimmune is a clinical-stage biopharmaceutical company founded in 2014 that develops antibody-based cancer therapeutics, focusing on bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs). The company operates across immuno-oncology with operations in Redmond, Washington and Princeton, New Jersey.
The company has built four proprietary platforms to advance its pipeline: the SEBA platform for bispecific antibodies, the HIRE ADC platform described as globally leading, the GNC platform for multi-specific antibodies, and the AIDP platform for AI-powered computational drug design. Multiple clinical-stage assets are advancing through trials in solid tumour and haematologic indications, supported by a robust preclinical pipeline.
Systimmune's lead programme, BL-B01D1 (iza-bren), an EGFRxHER3 bispecific ADC, is the subject of a significant global strategic collaboration with Bristol Myers Squibb for co-development and co-commercialisation. The company is led by a team of highly experienced R&D scientists and biotech professionals.
